MoonBiotech Closes Series B Worth ￥10M

According to lieyunwang.com, Moon (Beijing) Biotech Co., Ltd. ("MoonBiotech") has closed on a Series B financing round of tens of millions yuan, with participation from the existing investor Yuexiu Fund. Proceeds of this financing will be used for the research and development of microecological drugs, and the development and sales of microbial agents.

MoonBiotech is an innovative biotechnology company focusing on developing and commercializing microbe-based products and solutions. The company was founded in 2015 by a team of highly-qualified scientists and industry experts who are striving to look for new ways of protecting the environment and promoting the wellness of life.

MoonBiotech is dedicated to preserve and identify new microbial resources that are highly valuable to establish the biggest standardized microbial resources center in the world. Based on in-depth microbiological research and data mining, they select microorganisms and their metabolites that are bioactive to meet the eager and critical market needs ( biological agriculture, environmental governance, healthy food, and biomedicine) through high-throughput screening. The company aims to provide first-class microbial products and solutions to our customers.

At present, MoonBiotech has established a microbial diversity strain library that has nearly thousands of strain, more than a quarter of them the strain were separated and identified first in China, and a soil metagenomic DNA sample bank, that has collected nearly 10,000 metagenomic DNA samples.

In the field of metabolic diseases and tumor immunity, relying on its own bacteria resources and its team, MoonBiotech has cooperated with renowned pharmaceutical enterprises in the research and development of microecological drugs, to explore the combined drug treatment.

Yuexiu Fund was established by Yuexiu Financial Holding as an industrial fund in August 2011 with a registered capital of 100 million yuan. By December 2018, the company had AUM of more than 60 billion yuan. The company focuses on equity investments.